Description:

Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and the principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed with emphasis on mode of action, dose intensity and chemotherapy regimes. The range of side effects of cancer treatments will be studied in detail. Quality of life issues in terms of overall assessment and result interpretation will also be discussed.

Detailed consideration will be given to the treatment of major tumor types: breast, lung, melanoma, upper gastrointestinal (GI), colorectal, ovarian and prostate cancer. Each session will be presented by clinicians active in these areas and will focus on overall patient presentation and management and cancer diagnosis and staging. Following these sessions, our experts will lead delegates in interactive group discussions on the key issues relating to effective management of each tumor type.

The limitations of cytotoxic drugs currently available are well known. With this in mind, the course includes in-depth discussion on new drug development and identification of new pharmacological targets of particular interest and value. Clinical trial design issues will also be included.

Topics include:

- Cancer: terminology and classification
- Introduction to anti-cancer drugs and side effects
- New developments in cancer therapy
- Introduction to the major tumor types: breast, lung, melanoma, upper GI, colorectal, ovarian and prostate cancer
- Clinical trial issues in oncology

Course Instructors:

Jeffrey Crawford, MD
George Barth Geller Professor for Research in Cancer
Chief of Medical Oncology
Duke University Medical Center

Nancy A Dawson, MD
Professor of Medicine
Director, Genito-Urinary Oncology
Lombardi Cancer Center
Georgetown University

Stergios Moschos, MD
Clinical Associate Professor of Medicine
University of North Carolina at Chapel Hill

Bert O’Neil, MD
Associate Professor in Clinical Research
UNC Lineberger Comprehensive Cancer Center
Jeffrey Peppercorn, MD  
Assistant Professor of Medicine  
Division of Medical Oncology  
Duke University Medical Center

Russell Schilder, MD  
Chief, Gynecologic Medical Oncology  
Thomas Jefferson University

Who Should Attend:  
Healthcare’s courses are designed for both medical and non-medical staff within the pharmaceutical industry. This course is suitable for clinical research, medical information, regulatory affairs, biometrics and strategic marketing personnel.

Administrative/Venue Details:  
The registration fee at CHI’s VIP Discount Rate is $3,885 USD (regular rate $4,586 USD). You save 15% off your registration by registering through Cambridge Healthtech Institute (CHI). This includes lunch and refreshments throughout the day. Accommodation costs are not included. Delegates can register on-line or by completing the booking form and returning it together with the appropriate payment to Cambridge Healthtech Institute. Please retain a copy of the booking form for your records. Venue TBA. Details of the venue will be supplied on registration.

Schedule:  
May 22: 8:15 am – 5:30 pm  
May 23: 8:15 am – 3:15 pm

Course Schedule  
DAY 1 – Wednesday, May 22: 8:15 am – 5:30 pm

8:15 am Registration – Tea/coffee on arrival

8:30 Welcome/Opening Remarks

8:35 Introduction to Cancer
  • Clarification of terminology
  • Classification of tumor types
  • Principles of treatment and review of treatment options
    - chemotherapy
    - radiotherapy
    - surgical intervention
  • Adjuvant and neoadjuvant therapy
  • Endpoint assessment (response/survival)

9:30 Introduction to Anti-Cancer Drugs and Side Effects
  • Classification of anti-cancer drugs
  • Mechanisms of action
  • Mono vs. combination therapy
  • Chemotherapy regimes
  • Dose intensity and outcome

10:30 Tea/coffee

11:45 Lung Cancer
  • Epidemiology
  • Small vs. non small cell cancer
  • Patient presentation
  • Treatment options
    - surgery
    - chemotherapy
    - radiotherapy
12:45 Lung Cancer Case Presentations and Discussion

1:00 Lunch

2:00 Prostate Cancer
- Epidemiology
- Patient presentation
- Diagnosis and management
- Treatment of localized disease

3:15 Prostate Cancer Case Presentations and Discussion

3:30 Tea/coffee

3:45 Breast Cancer
- Epidemiology
- Diagnosis and staging
- Review of surgical procedures
- Chemotherapeutic options
- Role of hormonal therapy

5:15 Breast Cancer Case Presentations and Discussion

5:30 End of Day One

DAY 2 – Thursday, May 23: 8:15 am – 3:15 pm

8:15 am Tea/coffee on arrival

8:30 Ovarian Cancer
- Epidemiology
- Diagnosis and staging
- Review of surgical procedures
- Chemotherapeutic options
- Role of hormonal therapy

9:30 Ovarian Case Presentations and Discussion

9:45 Melanoma
- Epidemiology
- Classification
- Diagnosis, staging and prognosis
- Current treatment options, their strengths and limitations

10:45 Melanoma Case Presentation and Discussion

11:00 Tea/coffee

11:15 Upper Gastrointestinal (GI) Cancer (esophagus, stomach, pancreas)
- Epidemiology
- Patterns of presentation
- Diagnosis and management
- Surgery
- Chemotherapy
- Radiotherapy

12:15 GI Case Presentations and Discussion
12:30  Lunch

1:30  Colorectal Cancer
  • Epidemiology
  • Patterns of presentation
  • Diagnosis and management
  • Surgery
  • Chemotherapy
  • Other Treatment Options

2:45  Colorectal Case Presentations and Discussion

3:00  Closing Remarks

3:15  Departure
About our Course Instructors

Jeffrey Crawford

Dr. Jeffrey Crawford’s clinical interests are lung cancer (small cell and non-small cell), chemotherapy, hematopoietic growth factors and cancer clinical trials. His research interests are lung cancer/new treatment approaches, clinical trials of hematopoietic growth factors, biological agents and targeted drug development and cancer in the elderly and supportive care.

He was the Lead Investigator of the U.S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91, the Lead Investigator of the U.S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94 and the Principal Investigator in initial Phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.

Nancy Dawson

Dr. Nancy A. Dawson is the William M. Scholl Professor of Medicine and Oncology, Director of the Clinical Research Management Office and Director of Clinical Research in the Prostate Cancer Research Center at the Lombardi Comprehensive Cancer Center at Georgetown University. She previously was the Director of Genitourinary Medical Oncology at the University of Maryland Greenebaum Cancer Center from 1999 through 2006.

Dr. Dawson retired as a colonel in the United States Army in June, 1999. She served her entire military career at Walter Reed Army Medical Center where she was Director of Clinical Research, Chief of Hematology-Oncology Service, and Consultant to the Surgeon General of the Army. She also was a senior investigator in the signal Transduction and Oncogenesis Section of the Medical Branch of the National Cancer Institute.

She served as the Vice-Chair of the Prostate Committee for the Cancer and Leukemia Group B (CALGB) for a decade and has chaired several CALGB studies for prostate cancer. She is co-editor of Prostate Cancer (1994) and Prostate Cancer: Translational and Emerging Therapies (2006). She is currently focusing on novel systemic approaches to the treatment of prostate, bladder and kidney cancer.

Dr. Dawson earned her undergraduate degree from the University of California, Berkeley, and her medical degree, cum laude, from Georgetown University School of Medicine, Washington, D.C.

Stergios Moschos

Stergios Moschos is a Clinical Associate Professor of Medicine at the University of North Carolina Chapel Hill. He received his Medical Degree at the National and Kapodistrian University of Athens, Greece in 1997. He completed his Internal Medicine Residency at the Tufts-affiliated Newton-Wellesley Hospital, in Boston, MA followed by a clinical fellowship in Hematology/Oncology at the University of Pittsburgh Medical Center. He was appointed at the rank of Assistant Professor at the University of Pittsburgh Medical Center in 2005 where he remained an active member of the Melanoma and Skin Cancer Program until 2011. His research –basic, translational, and clinical- is focused on identifying molecules that are important for melanoma development and progression, identifying mechanisms of action of FDA-approved and investigational agents in melanoma. More recently, he participated in the pivotal trials leading to the F.D.A approval of vemurafenib in metastatic melanoma. Currently his research is focused on studying the biology of melanoma brain metastases, the role of metabolism in melanoma, as well as mechanisms of resistance to molecularly targeted therapies.

Bert H. O’Neil

Bert H. O’Neil, MD, is an Associate Professor in the Division of Hematology and Oncology at the University of North Carolina in Chapel Hill. Dr. O’Neil earned his BS in biology at the University of California in Irvine and his MD at the UCLA School of Medicine. After graduating, he completed his residency in internal medicine at the University of California in San Francisco. His fellowship in hematology and oncology also was conducted at the University of California in San Francisco.

Currently, Dr. O’Neil serves as Director of the Gastrointestinal Cancer Research Program at UNC and the Section
Chief of GI and GU malignancies at UNC. He is also a Cadre Member of the CALGB GI Committee and a CALGB Study Chair. Dr. O’Neil’s research interests include elucidation of novel mechanisms of resistance to radiation therapy in rectal cancer, and early drug development for gastrointestinal malignancies, particularly colorectal cancer and hepatocellular carcinoma.

**Jeffrey Peppercorn**

Dr. Peppercorn is a hematologist/oncologist with special interests in breast cancer, medical ethics, and trial accrual. He trained at Harvard Medical School, completed internal medicine residency at Massachusetts General Hospital, and completed his hematology/oncology fellowship training at the Dana-Farber Cancer Institute. His clinical specialty is breast cancer and he is currently an Assistant Professor of Medicine at Duke University. He also co-chairs the CALGB ethics committee. His research ranges from clinical trials of novel therapeutics for breast cancer to studies of accrual to clinical trials and medical ethics and he is the author of numerous publications, reviews, and chapters on these topics.

**Select Publications:**
# Course Registration Form

**Introduction to Oncology and Chemotherapy**

May 22-23, 2013  
Newark Liberty International Airport Marriott - Newark, NJ

*Fill out and fax back to James Prudhomme at +1 781-972-5425*

If you are paying by check or have any questions regarding payment, please call +1 781-972-5486. To inquire about a group discount, call +1 781-972-5472.

Fee: VIP Discount Rate $3,885 USD (regular rate $4,586 USD)

## YOUR DETAILS:

Title: (tick applicable)  
- Dr.  
- Mr.  
- Mrs.  
- Ms.  
- Miss  
- Other

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company</th>
<th>Job Title</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Department</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>City</th>
<th>State</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Telephone</th>
<th>Fax</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Charge my credit card

- VISA  
- MasterCard  
- American Express  
- Maestro*

*Only debit cards issued by a UK bank can be accepted.

<table>
<thead>
<tr>
<th>Name (as it appears on card)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Account Number</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Start Date (mm/yy)</th>
<th>End Date (mm/yy)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Security Number (from rear/front of card)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

---

**Please note:** No refund/credit of registration fee will be made for any cancellations received less than 20 working days prior to the date of the course. Cancellations made more than 20 working days prior to course date will incur a $175 (USD) administration fee. Substitutions may be made at any time. If Healthcare cancels or postpones this event, the registration fee will be refunded. Healthcare will not accept liability for any other costs. Healthcare reserves the right to amend the content and timing of all courses. Your details will be entered onto our database and we may, from time to time, advise you of other products that may be of interest to you. If you do not wish to receive this information then please let us know.